Abstract
A 70-year-old man with relapsed/refractory chronic lymphocytic leukemia has multiple comorbidities including atrial fibrillation (on warfarin for anticoagulation), irritable bowel syndrome, and chronic renal insufficiency. Two years ago, he received bendamustine and rituximab as first-line therapy for chronic lymphocytic leukemia and achieved partial response, but now has relapsed. Fluorescence in situ hybridization cytogenetics reveals deletion 17p. Which novel agent would you recommend for this patient?
© 2016 by The American Society of Hematology. All rights reserved.
MeSH terms
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Atrial Fibrillation / drug therapy*
-
Atrial Fibrillation / genetics
-
Atrial Fibrillation / metabolism
-
Atrial Fibrillation / pathology
-
Chromosome Deletion
-
Chromosomes, Human, Pair 17
-
Comorbidity
-
Humans
-
Irritable Bowel Syndrome / drug therapy*
-
Irritable Bowel Syndrome / genetics
-
Irritable Bowel Syndrome / metabolism
-
Irritable Bowel Syndrome / pathology
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
-
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
-
Male
-
Renal Insufficiency, Chronic / drug therapy*
-
Renal Insufficiency, Chronic / genetics
-
Renal Insufficiency, Chronic / metabolism
-
Renal Insufficiency, Chronic / pathology
-
Safety*
-
Smith-Magenis Syndrome
-
Warfarin / therapeutic use*
Substances
-
Antineoplastic Agents
-
Warfarin